Skip to main content
Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial

Fig. 2

The Cost-effectiveness Acceptability Curves for Serplulimab plus CF Strategy Compared to Placebo plus CF Strategy in the Overall Patients (A), Patients with PD-L1 Expression Level of 1 ≤ CPS < 10 (B), Patients with PD-L1 CPS ≥ 10 (C). Abbreviation: QALY, quality-adjusted life-year; CF, cisplatin and 5-fluorouracil

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us